Description
Triple GLP-1 / GIP / glucagon receptor agonist for obesity
Retatrutide is a cutting-edge peptide formulation designed to enhance weight loss by regulating appetite, increasing fat metabolism, and improving energy balance. Activates GLP-1, GIP, and glucagon receptors, involved in appetite suppression and promoting feelings of fullness. Helps boost fat oxidation, enhancing the body’s ability to utilize stored fat for energy. May also help regulate blood sugar levels and improve insulin sensitivity.
- Abdrabou Abouelmagd A, et al. Efficacy and safety of retatrutide, a novel GLP-1, GIP, and glucagon receptor agonist for obesity treatment: a systematic review and meta-analysis of randomized controlled trials. Proc (Bayl Univ Med Cent). 2025;38(3):291-303. PMID: 40291085 | DOI: 10.1080/08998280.2025.2456441
- Katsi V, et al. Retatrutide – A Game Changer in Obesity Pharmacotherapy. Biomolecules. 2025;15(6):796. PMID: 40563436 | DOI: 10.3390/biom15060796
- Locatelli JC, et al. Incretin-Based Weight Loss Pharmacotherapy: Can Resistance Exercise Optimize Changes in Body Composition? Diabetes Care. 2024;47(10):1718-1730. PMID: 38687506 | DOI: 10.2337/dci23-0100
